Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             38 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A critical moment for health care The Lancet Respiratory Medicine,

9 12 p. 1343
artikel
2 Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial Ehrmann, Stephan

9 12 p. 1387-1395
artikel
3 Awake prone positioning in COVID-19: is tummy time ready for prime time? Weatherald, Jason

9 12 p. 1347-1349
artikel
4 Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial Kalil, Andre C

9 12 p. 1349-1351
artikel
5 Breathing lessons: a doctor's guide to lung health Paterson, Bri

9 12 p. 1362
artikel
6 Charting a course for the management of long COVID Beasley, Richard

9 12 p. 1358-1360
artikel
7 Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
9 12 p. 1419-1426
artikel
8 Colchicine treatment in COVID-19: the remaining unsolved question Rojas-Villarraga, Adriana

9 12 p. 1351-1353
artikel
9 Correction to Lancet Respir Med 2021; 9: 340–42
9 12 p. e114
artikel
10 Correction to Lancet Respir Med 2019; 7: 745–56
9 12 p. e114
artikel
11 Correction to Lancet Respir Med 2021; 9: 1377–86
9 12 p. e114
artikel
12 Correction to Lancet Respir Med 2021; published online Nov 9. https://doi.org/10.1016/S2213-2600(21)00414-8
9 12 p. e114
artikel
13 Correction to Lancet Respir Med 2021; published online Oct 1. https://doi.org/10.1016/S2213-2600(21)00352-0
9 12 p. e114
artikel
14 COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study Agrawal, Utkarsh

9 12 p. 1439-1449
artikel
15 COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions Lascarrou, Jean-Baptiste

9 12 p. 1345-1347
artikel
16 Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Milne, Gregory

9 12 p. 1450-1466
artikel
17 Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial Declercq, Jozefien

9 12 p. 1427-1438
artikel
18 Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial Marconi, Vincent C

9 12 p. 1407-1418
artikel
19 Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial Kalil, Andre C

9 12 p. 1365-1376
artikel
20 Global tuberculosis progress reversed by COVID-19 pandemic Kirby, Tony

9 12 p. e118-e119
artikel
21 Has Spain reached herd immunity? Kirby, Tony

9 12 p. e120
artikel
22 Invisible demons Burki, Talha Khan

9 12 p. 1362-1363
artikel
23 Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts Bos, Lieuwe D J

9 12 p. 1377-1386
artikel
24 Long-term outcomes of EVALI: a 1-year retrospective study Triantafyllou, Georgios A

9 12 p. e112-e113
artikel
25 Nintedanib for treating progressive fibrosing interstitial lung diseases Adler, Amanda I

9 12 p. e116-e117
artikel
26 Philip Morris International purchases Vectura Burki, Talha Khan

9 12 p. e122
artikel
27 Prone positioning might reduce the need for intubation in people with severe COVID-19 McGuire, W Cameron

9 12 p. e110
artikel
28 Prone positioning might reduce the need for intubation in people with severe COVID-19 – Authors' reply Ibarra-Estrada, Miguel

9 12 p. e111
artikel
29 Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan Hsieh, Szu-Min

9 12 p. 1396-1406
artikel
30 Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes Leshem, Eyal

9 12 p. 1354-1356
artikel
31 Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial Wilkinson, Tom

9 12 p. 1344-1345
artikel
32 The course of action for effective anti-cytokine treatment in COVID-19 Cavalli, Giulio

9 12 p. 1353-1354
artikel
33 The first wave Burki, Talha Khan

9 12 p. 1361
artikel
34 The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease Adeloye, Davies

9 12 p. 1467-1478
artikel
35 Undetected COVID-19 cases in Africa Burki, Talha Khan

9 12 p. e121
artikel
36 US FDA delays decision on Juul and other leading e-cigarette brands Furlow, Bryant

9 12 p. e115
artikel
37 Venus and Mars: chest wall deformity and thoracic disease Ashrafian, Hutan

9 12 p. 1363-1364
artikel
38 Waning immunity to SARS-CoV-2: implications for vaccine booster strategies Altmann, Daniel M

9 12 p. 1356-1358
artikel
                             38 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland